Dapagliflozin in high-risk T2DM reduces hospitalization for HF, but does not reduce death, MI, or stroke (DECLARE-TIMI 58)
There's more to see -- the rest of this topic is available only to subscribers.
© 2000–2024 Unbound Medicine, Inc. All rights reserved